3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
4
Gastrointestinal
3
Thoracic
2
Lymphoid
2
Head & Neck
2
Dermatologic
2
CNS
2
Myeloid
1
Conditions
Lymphoma
666
Lymphoma, Non-Hodgkin
593
Leukemia, Lymphocytic, Chronic, B-Cell
535
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Lymphoma, Follicular
418
Lymphoma, Large B-Cell, Diffuse
379
Leukemia
358
Hodgkin Disease
354
Lymphoma, Mantle-Cell
306
Leukemia, Myeloid, Acute
250
Multiple Myeloma
237
Myelodysplastic Syndromes
214
Lymphoma, B-Cell, Marginal Zone
196
Recurrence
195
Burkitt Lymphoma
189
Waldenstrom Macroglobulinemia
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
130
Lymphoma, B-Cell
127
Neoplasms
118
Lymphoma, T-Cell, Cutaneous
116
Lymphoma, Large-Cell, Anaplastic
113
Hematologic Neoplasms
103
Lymphoma, Large-Cell, Immunoblastic
100
Mycosis Fungoides
95
Myeloproliferative Disorders
94
Sezary Syndrome
86
Lymphoma, T-Cell, Peripheral
83
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
81
Lymphoma, T-Cell
74
Primary Myelofibrosis
70
Interventions
parsaclisib
1
duvelisib
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Lymphoid
×
Clear all
NCT03126019
2025-03-14
CITADEL-203
Incyte Corporation
Phase 2
Completed
126 enrolled
15 charts
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA